Specifically, MMP-9 can bind to a docking complex formed by α4β1 integrin and 190 kDa CD44v on the CLL cell surface, potentially enhancing its catalytic activity and facilitating the invasiveness of CLL cells [28]. This evidence concerns the gene MMP9 and B-cell chronic lymphocytic leukemia.